Critical Care

official impact factor 4.60

This article is part of the supplement: Severe sepsis and drotrecogin alfa (activated)

Highly Access Email this article to a friend

Practical aspects of treatment with drotrecogin alfa (activated)

Luigi Camporota and Duncan Wyncoll*

Critical Care 2007, 11(Suppl 5):S7 doi:10.1186/cc6158

Fields marked * are required


Multiple email addresses should be separated with commas or semicolons.